The increase in price target from $8 to $11 by TD Cowen reflects a positive outlook on Ocular Therapeutix's future performance. This adjustment suggests that the analyst sees potential for growth or improvement in the company's stock value, which could lead to increased investor interest and potentially drive the stock price up in the short term.